Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
AssigneeViventia Biotechnologies Inc.
InventorsJeannick Cizeau, Francina C. Chahal
Life of this patent
Estimating the term…
Abstract
The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof.
Claims39
An antibody or an antigen binding fragment thereof that specifically binds to prostate stem cell antigen (PSCA) or a variant heterogeneous ribonucleoprotein G (HnRNPG), said antibody comprising a heavy chain variable region comprising complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 10, 11, and 12 and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOs:
- 7, 8, and 9.
A detectably labeled antibody or an antigen binding fragment thereof that specifically binds to prostate stem cell antigen (PSCA) or a variant heterogeneous ribonucleoprotein G (HnRNPG), said antibody comprising a heavy chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOs:
- 10, 11, and 12 and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOs:
- 7, 8, and 9.
Dependencies are inferred from the claim text.